# Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients

> **NCT00034385** · PHASE4 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 12 (—)

## Conditions studied

- Kidney Trasplant

## Interventions

- **DRUG:** Valganciclovir

## Key facts

- **NCT ID:** NCT00034385
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04-24
- **Primary completion:** 2007-01-30
- **Final completion:** 2009-10-30
- **Target enrollment:** 12 (—)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00034385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00034385, "Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00034385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*